A New Study by Kilo Health Ranks 5 Conditions That Are the Most Dangerous to Cardiovascular Health

Kilo Health released a report that shows the ranking of the top 5 health conditions that are common among Americans. Having diabetes and smoking took a surprisingly low place on the list.

The company has surveyed 11,408 Americans with high cholesterol and high blood pressure. It revealed that the top two common factors among heart patients are low levels of physical activity (75%) and obesity (74%).

“Exercise lowers blood pressure, increases oxygen amount in the blood, and strengthens the heart muscle. Also, it helps prevent the development of diabetes, maintain weight, and reduce hypertension. All of these are independent risk factors for heart disease,” said Robertas Pranevicius, MD, Medical Advisor for Cardiovascular Disease Management at Cardi.Health, a subsidiary company of Kilo Health.

However, the survey has uncovered some other surprising factors that impact heart health. 28% of respondents said they have food allergies, only 15% revealed they have diabetes, and 6% mentioned that they smoke.

While food allergies might not be directly impacting cardiovascular health, they reduce the overall quality of life. However, the most interesting finding of the survey is that diabetes ranks quite low on the ranking. It takes 4th place, even though it’s one of the most dangerous comorbidities that accelerates heart disease.

“People who have diabetes should regularly pay a visit to a cardiologist. Diabetes damages the nerves, and people who have it should be checked out as soon as possible,” added Pranevicius.

Finally, smoking came in last place on the ranking. This is not very surprising as smoking in the US is in decline in general. According to the CDC, 20.9% of Americans smoked in 2015, but the number dropped to 12.5% in 2020. Full report here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version